课题基金 / 基金详情

Transcriptional Regulation of the Immune Response

Transcriptional Regulation of the Immune Response
免疫反应的转录调节
批准号:
8092054
负责人:
LAURIE Hollis GLIMCHER
金额:
$22.94万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-06-28 至 2012-05-31

项目摘要

项目成果

LAURIE Hollis GLIMCHER的其他基金

相似基金

相关文献

中文摘要
翻译
描述(申请人提供):在目前的资助期间,我们发现了我们实验室分离的转录因子XBP-1,它是浆细胞分化和抗体产生所必需的。XBP-1是IRE1a(IRE1)的唯一底物,IRE1a是内质网跨膜内切核酸酶和激酶,介导未折叠蛋白反应(UPR)。我们的研究已经建立了浆细胞分化与UPR之间的联系。我们已经提供了证据,证明XBP-1在B细胞和腺泡细胞中具有扩大分泌机制的功能,并且在树突状细胞的存活中起重要作用。此外,XBP-1是蛋白酶体抑制剂治疗多发性骨髓瘤的主要靶点。XBP-1 FLOX/FLOX小鼠品系的可获得性以及在当前资助期产生的IRE/淋巴嵌合体将使我们能够探索IRE1、XBP-1和UPR在前B细胞(IRE1)和浆细胞(XBP-1)分化、在正常和恶性树突状细胞生存和功能、自身免疫性疾病和多发性骨髓瘤中的功能等许多悬而未决的问题。在下一个资助阶段,我们建议1)进一步探讨XBP-1在B细胞承诺中的作用。2)确定IRE1信号通路的新成分。3)研究XBP-1和UPR在正常和恶性树突状细胞(DC)中的作用。4)研究XBP-1在自身免疫性疾病中的作用。5)研究XBP-1在浆细胞肿瘤发生和增殖中的需求。
英文摘要
DESCRIPTION (provided by applicant): In the current funding period, we have discovered that the transcription factor XBP-1, isolated in our laboratory, is required for plasma cell differentiation and antibody production. XBP-1 is the only substrate of IRE1a (IRE1), the ER transmembrane endoribonuclease and kinase that mediates the Unfolded Protein Response (UPR). Our studies have established a link between plasma cell differentiation and the UPR. We have provided evidence that XBP-1 functions to expand the secretory machinery in B cells and acinar cells and is important in dendritic cell survival. Further, XBP-1 is a major target of proteasome inhibitors in the treatment of multiple myeloma. The availability of an XBP-1 flox/flox mouse strain as well as IRE-/- lymphoid chimeras generated in the current funding period will allow us to explore many unanswered questions about the function of IRE1, XBP-1 and the UPR in pre B (IRE1) and plasma cell (XBP-1) differentiation, in normal and malignant dendritic cell survival and function, in autoimmune disease and in multiple myeloma. In the next funding period we propose to 1) Further explore the role of XBP-1 in B cell commitment.2) Identify novel components of the IRE1 signaling pathway. 3) Investigate the function of XBP-1 and the UPR in normal and malignant dendritic cells (DCs). 4) Examine the role of XBP-1 in autoimmune disease.5) Investigate the requirement of XBP-1 for the development and propagation of plasma cell neoplasms.
期刊论文(37)
专著(0)
科研奖励(0)
会议论文
Inhibition of IFN-gamma induction of class II MHC genes by cAMP and prostaglandins.
cAMP 和前列腺素抑制 II 类 MHC 基因的 IFN-γ 诱导。
DOI: 10.1016/0162-3109(94)90008-6
发表时间: 1994
期刊: Immunopharmacology
影响因子: --
作者: [Ivashkiv,LB, Ayres,A, Glimcher,LH]
通讯作者: Glimcher,LH
DOI: 10.1016/j.ijrobp.2004.06.130
发表时间: 2004-09
期刊: Cancer research
影响因子: 11.2
作者: [L. Romero-Ramírez;H. Cao;Daniel W. Nelson;E. Hammond;Ann-Hwee Lee;H. Yoshida;K. Mori;L. Glimcher]
通讯作者: L. Romero-Ramírez;H. Cao;Daniel W. Nelson;E. Hammond;Ann-Hwee Lee;H. Yoshida;K. Mori;L. Glimcher
DOI: 10.1053/j.gastro.2011.06.045
发表时间: 2011-10
期刊: Gastroenterology
影响因子: 29.4
作者: [Hess DA, Humphrey SE, Ishibashi J, Damsz B, Lee AH, Glimcher LH, Konieczny SF]
通讯作者: Konieczny SF
DOI: 10.1084/jem.183.3.1063
发表时间: 1996-03-01
期刊: The Journal of experimental medicine
影响因子: --
作者: [Douhan J 3rd, Hauber I, Eibl MM, Glimcher LH]
通讯作者: Glimcher LH
共 19 条
    Developing a pragmatic guide to implementing social risk referrals: A partnership between Caring Health Center (CHC) and the Implementation Science Center for Cancer
    • 批准号:
      10822141
    • 项目类别:
    • 资助金额:
      $22.47万
    • 财政年份:
      2023
    • 负责人:
      LAURIE Hollis GLIMCHER
    • 依托单位:
    Understanding the impact of an EHR-integrated hereditary cancer risk assessment application on patient-provider communication
    • 批准号:
      10831167
    • 项目类别:
    • 资助金额:
      $10.0万
    • 财政年份:
      2023
    • 负责人:
      LAURIE Hollis GLIMCHER
    • 依托单位:
    Real-World Molecularly Targeted Treatment Registry (MaTTeR): a Pilot Study to Enrich CCDI Data Utilizing Directed Electronic Medical Record (EMR) Extraction
    • 批准号:
      10878384
    • 项目类别:
    • 资助金额:
      $49.59万
    • 财政年份:
      2023
    • 负责人:
      LAURIE Hollis GLIMCHER
    • 依托单位:
    Repurposing Bruton's tyrosine kinase (BTK) inhibitors to reverse immunosuppression in high-grade serous ovarian cancer (HGSC)
    • 批准号:
      10661823
    • 项目类别:
    • 资助金额:
      $8.9万
    • 财政年份:
      2022
    • 负责人:
      LAURIE Hollis GLIMCHER
    • 依托单位:
    海外基金